Intraluminal Pancreas Function and Hormonal Control

**EFFECT OF INTRADUODENAL ADMINISTRATION OF OVALBUMIN (OVA) AND HCl VS. INTRAVENOUS INFUSION OF CCK 33 AND SECRETIN ON EXOCRINE PANCREATIC SECRETION IN PIGS AND RABBITS.**


Department of Animal Physiology, University of Lund, Lund, Sweden.

In early mammalian postnatal life milk exhibits low stimulatory effects on the exocrine pancreas function as compared to the effects of solid food in adults. Moreover, in newborn and young mammals the pancreatic function is immature and the gastrointestinal hormones generally have a low potency to stimulate the exocrine pancreas.

In order to study the development of regulatory mechanisms of the exocrine pancreas, 11 pigs were surgically prepared 2 weeks before weaning for long-term collection of pancreatic juice. Experiments (lasting for 2.5 h) were performed every second day, starting two days after the surgical procedures and 2 days after weaning (performed at 4 weeks of age). Pancreatic juice was collected in plastic tubes on ice bath, during 15 min intervals. After a baseline period (the first 30 min), three-minute control infusions of either 5 ml saline/kg intraduodenally (i.d.) or 2 ml saline + 0.5% BSA/kg intravenously (i.v.) were done. Followed by a treatment (3×30 min) with increasing doses of: OVA (5, 50, 500 mg/kg, i.d.) or CCK 33 (10, 50, 250 μmol/kg, i.v.) or HCl (0.025, 0.25, 2.5 mmol/kg, i.d.) or secretin (22, 110, 440 μmol/kg, i.v.). All treatments were performed once before and twice after weaning.

I.d. infusion of OVA and i.v. administration of CCK 33 did not affect pancreatic exocrine secretion, whereas i.d. HCl infusion before weaning stimulated pancreatic juice outflow from 1.1 to 2.1 ml/kg/h and after weaning from 2 to 3.5 ml/kg/h. The protein output increased from 2.5 to 4.0 mg/kg/h.

Secretin i.v. infusion stimulated the volume outflow from 1 to 2 ml/kg/h before weaning and from 2 to 6 ml/kg/h after weaning and the protein output from 2.5 to 6 mg/kg/h. Trypsin activity outflow was also increased but was obtained after 1 to 2 U/kg/h before weaning but from 3 to 6 U/kg/h 3-4 weeks after weaning.

In conclusion, the secretin and HCl dependent stimulatory mechanisms of the exocrine pancreas are already in function before weaning in pigs, although the effects are enhanced after weaning. Surprisingly i.d. infusion of the protein OVA CCK 33 did show very low, if any, stimulatory effects on exocrine pancreas neither before nor after weaning.

**INFLUENCE OF TRYPTOPHAN-RELEASING HORMONE (TRH) AND ITS METABOLITES CYCLO (HIS-PRO) ON AMYLASE SECRETION FROM ISOLATED RAT EXOCRINE PANCREATIC ACINAR CELLS.**


Department of Internal Medicine 1, University of Ulm, Germany; *Department of Internal Medicine, University of Rome, Italy.

The exocrine pancreas contains high amounts of TRH, and exogenous TRH inhibits in vivo pancreatic protein secretion in a dose-dependent manner. Aim of our study was to investigate the direct effect of TRH and its metabolites Cyclo (His-Pro) on rat exocrine pancreatic acinar cells.

Methods: Isolated acinar cells from rat exocrine pancreas were obtained by a collagenase digestion technique. Amylase release from acinar cells was determined during a 40 min-incubation period at 37°C under basal and secretagogues-stimulated conditions.

Results: TRH did not affect basal amylase release in concentrations from 10^-14 M to 10^-7 M. TRH inhibited carbachol (10^-2 M)-stimulated amylase release by 24% at a concentration of 10^-8 M. Cyclic peptide (3×10^-10 M) -stimulated amylase secretion was maximally reduced by 23% at a TRH concentration of 10^-10 M. Direct stimulation of proteinkinase G-mediated secretion by the dicacylglycerol analog 1-acyl-L-arachidonoyl glycerol (AAG, 5×10^-4 M) was not altered by TRH. The TRH metabolite Cyclo (His-Pro) did not influence basal or stimulated pancreatic secretion.

Conclusions: In contrast to the TRH metabolite Cyclo (His-Pro), TRH shows a direct inhibitory effect on receptor-stimulated secretion of carbachol- and cyclic peptide-induced enzyme secretion, whereas cyclo (His-Pro) did not significantly influence these findings, pointing to a TRH-induced modulation of exocrine pancreatic secretion at the receptor site.

**PANCREATIC ELASTASE (E1) IN FECES: A NEW TUBELESS PANCREATIC FUNCTION TEST.**


The proteolytic pancreatic enzyme E1 has a strikingly high stability and sensitivity, and is not changed in the feces. Because of a lack of sensitive, adequately evaluated and feasible tests of pancreatic function, we investigated E1 in the feces.

424 stool samples from 136 individuals were diluted and E1 was measured quantitatively by an enzyme-linked immunosorbent assay using monoclonal antibodies (Clin. Bioch. 1989,22:80-89). The results were compared with the Monotest Chymotrypsin (Fa. Boehringer Mannheim) and the Pancreolauryl-Test (PLT) (Fa. Tecmier, Marburg, Germany), two available indirect pancreatic function tests. The reference values of E1: pathological pancreatic function when E1 < 100 mg/g feces, borderline function from 100 up to 200 mg/g feces and normal exocrine function when E1 > 200 mg/g feces.

Activity levels of E1, Chymotrypsin and PLT agreed in 89 (62.4%) cases, only of E1 and Chymotryn in 108 (79.4%) and of E1 and PLT in 103 (75.4%) cases.

There is a good correlation between E1 and other established indirect exocrine function tests. Quantitative estimation of E1 measurement by ELISA is advantageous as compared with Chymotrypsin and PLT because of lack of interference by pancreatic enzyme replacemant therapy, high sensitivity and specificity and because of the possibility of automated analysis.

**NITRIC OXIDE (NO)-PRODUCING NEURONS IN THE MAMMALIAN PANCREAS.**

R. M. Giroio, W. Bracha**, A. Tucci, R. Corinaldesi, L. Francosoo, M. P. Scrosati, W. G. Olivi, Dept. of Internal Medicine & Gastroenterology, University of Bologna, Italy; *Depts. of Anatomy & Cell Biology, and Medicine; **CURE, VAMC-Wadsworth, UCLA School of Medicine, Los Angeles, CA, USA.

One of the major neuronal supply of the mammalian pancreas is represented by intrapancreatic innervation; and it is the most abundant. NO, a newly identified putative neurotransmitter, is able to stimulate the exocrine secretion in the isolated porcine pancreas and to induce insulin release. The formation of NO is dependent upon the activation of the constitutive enzyme NO synthase, which is identical to NADPH-diaphorase (NADPH-D). Using NADPH-D histochemical technique, we evaluated: 1) whether the pancreatic innervation includes NO-containing neurons; and 2) the possible targets of NADPH-D positive nerves. Pancreatic tissues from cats, dogs, pigs, monkeys (Macaca Fuscus) and humans (normal transplant donors) were fixed in Bouin's solution and cryoprotected in 25% sucrose. Tissues were sectioned (10-15 μm) with a cryostat and stained with NADPH-D technique. NADPH-D labeled nerves and neuronal cell bodies were identified in each of the mammalian pancreas examined. Overall, NADPH-D nerve processes were particularly abundant throughout the acini with the following density: cat and pig > dog and monkey > human. In all species, the intrapancreatic ganglia showed numerous neuronal cell bodies positive for NADPH-D. The density of NADPH-D labeled neurons was cat and monkey > dog and pig > human. The vasculature, ducts and endocrine tissue showed the least abundant NADPH-D innervation. There were no evident differences among the species studied except for the pig ilea where NADPH-D nerve endings were not detectable.

In conclusion, our results showed that: 1) NO-producing neurons are a major component of the pancreatic innervation; and 2) the identification of intrapancreal neurons markedly reactive for NADPH-D is consistent, at least partially, with an intrinsic origin of NADPH-D positive nerves. The diversity of the targets of NO containing nerves in the pancreas suggests that NO may influence different pancreatic functions.
ROLE OF VARIOUS PHOSPHOLIPASES-A2 (PLA-2) AND INHIBITORS IN THE PATHOGENESIS AND TREATMENT OF ACUTE EXPERIMENTAL PANCREATITIS. J. Mössner, C. Wessig, W. Fischbach. Med. Poliklinik, Univ. of Würzburg, FRG.

We have reported that lipolytic enzymes, such as lipase, CP, and PLA-2, by their ability to release fatty acids from lysolipids and destroy acinar cells (Pancreas 1992;8:70). We now studied which forms of PLA-2 is responsible for cellular damage and how such PLA-2 affects acinar cells. Isolated rat pancreatic acini were further incubated in buffer to which various factors, such as pure pancreatic PLA-2, bee-venom PLA-2, homogenates of leukocytes, homogenates of pancreas all +/- lecithin and +/- potential inhibitors (cis-stearat-emissate, aprotinin, CDP-choline, BM 16.2131, quinacin, albumin) were added. Cytotoxic destruction was measured by the degree of release of labeled proteins. PLA-2 alone was not harmful within 30 min of incubation. However, incubation of acini with either bee-venom or pancreatic PLA-2 in combination with lecithin caused rapid cellular destruction. Addition of high concentrations of trypsin activated pancreatic homogenates both alone and + lecithin caused cellular destruction suggesting that pancreatic PLA-2 uses lecithin from pancreatic membranes as substrate. Homogenates of rat or mouse leukocytes could not be able to destroy isolated acinar acini due to a much lower PLA-2 concentration as compared to the PLA-2 content present in pancreatic homogenates. All inhibitors besides albumin were not able to inhibit the destruction caused by pancreatic PLA-2 and lecithin. Conclusions: Pancreatic PLA-2 and not PLA-2 from infiltrating leukocytes may play a role in cellular necrosis of acute pancreatitis provided that its substrate is lecithin. Lecithin may originate from cellular membranes destroyed by other mechanisms. For further studies in vivo one needs specific inhibitors of pancreatic PLA-2 which are not available yet.


The biochemical and molecular mechanisms that underlie the pathophysiology of chronic pancreatitis (CP) are completely unknown. Recently, transforming growth factor alpha (TGF-α) and its receptor (TGF-αR) have been found to exhibit CP-like histological changes in the pancreas. TGF-α binds and activates the epidermal growth factor receptor (EGFR). Therefore, we analyzed TGF-α and EGFR expression in human CP tissues. Patients: CP tissue samples were obtained from 27 patients (23 men, 4 women, median age: 43 (range 23-56 years) undergoing surgery for CP. 17 pancreas from healthy organ donors served as controls. Methods: TGF-α and EGFR expression was studied by immunohistochemistry, using specific monoclonal antibodies, and by in situ hybridization and Northern blot analysis, using specific cRNA probes. Results: By immunohistochemistry, TGF-α and EGFR were expressed at high levels in both acinar cells and ductal cells in CP tissues. Northern blot analysis indicated that by comparison with normal controls, 10 of 11 CP tissues exhibited 2-fold increased TGF-α mRNA levels and 13 of 19 CP tissues exhibited a 6.0-fold increase in EGFR mRNA levels. In situ hybridization confirmed that overexpression occurred in both acinar and ductal cells, and indicated that both mRNA moieties co-localized with their respective proteins. Conclusion: Our findings suggest that TGF-α may act through autocrine and paracrine mechanisms and excessively activate the overexpressed EGFR in CP, thereby contributing to the histological and pathophysiological changes that occur in this disorder.


Recently, a radionuclide somatostatin analogue (111 In-paneterosine, "OctreoScan 111", Mallinkrodt Diagnostica, Petten Holland) has been proposed for "in vivo" detection of somatostatin-receptor bearing tumors. We have investigated the diagnostic efficacy of OctreoScan 111 scintigraphy to localize tumor lesions in 19 patients with biochemical (111 In) and/or histological (H/P) diagnosis of GEP-tumor (gastrinomas: 13; carcinoids: 2; somatostatinations: 2; Vip-oma: 1; Men-II: 1). Each patient was studied 4, 24 and 48 hours after injection of 180-220 MBq of OctreoScan 111. Total body planar and SPECT images were obtained using a gamma camera (Starcam 2000,GE, Milwaukee, USA) equipped with a medium energy parallel collimator. The scintigraphic results were compared with CT (Phillips Tomoscan LX) and MR (Phillips Gyroscan T5) images performed within one month. Results: The same findings were observed in the planar and SPECT images obtained at 4, 24 and 48 hours after OctreoScan 111 injection, indicating that early images were not affected by interfering background radioactivity. OctreoScan 111 detected tumor lesions in all patients except the patient with MEN-II, who at the time of the study had non-active disease. - because previously had tumor lesions (pheochromocytoma and non functional pancreatic tumor) resected. A single abdominal localization was visualized in 9 out of 13 patients with ZES, of whom 5 had tumors located in the liver and 4 in pancreatic-duodenal region, in the remaining 4 patients multiple abdominal localizations were observed. CT and MR respectively visualized lesions in 5 out of 13 (38,5%) and in 7 out of 13 (53,8%) patients, size 0.7-2.5 cm.; all these lesions were also detected by OctreoScan 111 scintigraphy. The two somatostatinomas, one carcinoid and the VIP-oma patient had multiple hepatic and/or abdominal multiple extrapancreatic lesions observed with OctreoScan and CT. In addition OctreoScan visualized a metastatic hepatic lesion in the other carcinoid patient and two chest lesions in VIP-oma patient, both were not observed with CT. The diagnostic advantages of 111 In-pentetreotide compared with other imaging techniques are probably due to the capability of OctreoScan 111 to visualize, independently from size, tumoral lesions having somatostatin receptors. These data suggest that this single and non invasive diagnostic procedure is able to successfully localize primary and/or metastatic lesions and could be the first imaging study to be performed in all GEP-tumors.

DIAGNOSIS AND DIFFERENTIATION OF PANCREATIC TUMORS: COMPARISON OF ENDOSONOGRAPHY, COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING. C. Meyerberger, R. Manni**el, R. Scherer, P. Bertschinger, H.P. Wirth, Th. Bischoff, R. Joel, R. Ammann, J. Altorfer. Deps. of Medicine (Gastroenterology Unit) and Radiology*, University Hospital of Zurich, Switzerland.

Endoscopic ultrasound (EUS) has gained a central role in the diagnosis of pancreatic disease. The purpose of this study was to assess the value of EUS, computed tomography (CT) and magnetic resonance imaging (MRI) imaging in diagnosing pancreatic tumors.

Patients and Methods: Forty patients (26, 1, 34, male age 60 years) with clinically suspected pancreatic tumor were evaluated in a prospective study with EUS (n=40), CT (n=52) and MRI imaging (n=28). EUS was performed with a 7.5 MHz Olympus echosoundoscope. The final diagnosis was made by surgery (n=34), or biopsy (n=10) combined with follow-up examinations (n=26, mean follow-up 16 months; range 11-25 months). There were 23 malignant, 8 benign and 9 inflammatory tumors. In 20 patients a tumor was excluded. Results: Sensitivity of EUS, CT and MRI imaging in diagnosing pancreatic tumor was 62 %, 58 % and 73 %, respectively. Specificity of EUS, CT and MRI imaging was 100 %, 94 % and 100 %, respectively. The overall accuracy of EUS was 95 % of CT 60 %; and of MRI 75 %. The sensitivity of EUS (n=21), CT (n=20) and MRI imaging (n=15) for small tumors - 3 cm (n=21) was 91 %, 40 % and 53 %, respectively. EUS correctly classified the inflammatory nature of the tumor in 7 of 9 patients (89 %) as proven by laparoscopy (n=9) and histological examinations. The correct diagnosis was given by CT in 1 of 8 patients (13 %). MRI imaging (n=3) falsely classified all inflammatory lesions as malignant tumors. Conclusion: 1.EUS was more accurate than CT and MRI imaging in diagnosing pancreatic tumors 2: EUS was significantly superior to CT and MRI imaging in detecting small pancreatic tumors. 3. Although all three modalities had limitations in the differentiation between malignancy and focal pancreatitis, EUS was superior to CT and MRI imaging in this respect.